Zhimeng Biotechnology is a Chinese biopharmaceutical company focused on developing innovative small molecule therapeutics targeting the NLRP3 inflammasome and related innate immune pathways. Based in Shanghai, the company leverages China's growing expertise in drug discovery and global partnerships to advance its pipeline of NLRP3 inhibitors for neurodegenerative and inflammatory diseases.
| Attribute | Value |
|---|---|
| Founded | 2018 |
| Headquarters | Shanghai, China |
| CEO | Dr. Wei Zhang |
| Funding | Series B ($40M, 2023) |
| Focus | NLRP3 inhibitors, innate immunity |
| Stage | Preclinical/IND-enabling |
Zhimeng operates with a hybrid model:
Zhimeng's NLRP3 program is built on:
The company focuses on developing next-generation NLRP3 inhibitors with:
| Program | Mechanism | Indication | Stage | Status |
|---|---|---|---|---|
| ZM-001 | NLRP3 inhibitor | Parkinson's disease | Preclinical | IND-enabling |
| ZM-002 | NLRP3 inhibitor | Osteoarthritis | Preclinical | Lead optimization |
| ZM-003 | NLRP3/TNFR dual | Inflammatory bowel disease | Discovery | Early stage |
ZM-001 is Zhimeng's lead program for Parkinson's disease:
The company has completed GLP toxicology studies and plans to file IND in 2025.
ZM-002 targets peripheral inflammation in osteoarthritis:
Zhimeng has established partnerships with leading Chinese research institutions:
Zhimeng's strategy includes:
| Round | Amount | Year | Investors |
|---|---|---|---|
| Series A | $12M | 2019 | Hillhouse Capital, Qiming Venture |
| Series B | $40M | 2023 | Hillhouse Capital, Legend Capital |
Zhimeng represents China's entry into the NLRP3 inhibitor space:
| Company | Location | Strength |
|---|---|---|
| Zhimeng | China | Cost-effective R&D, large patient pool |
| Olacteant | US | Clinical data |
| NodThera | UK | CNS expertise |
| Ventus | US | Dual-target platform |
| IFM/BMS | US | Big pharma resources |